CD44 is a highly glycosylated transmembrane protein that modulates a variety of cellular functions including adhesion, proliferation, presentation of growth factors, apoptosis, cell migration and metastatic behaviour. CD44 is encoded by a complex gene containing 20 exons, many of which are subject to alternative mRNA splicing resulting in a large number of possible transcripts. The most common form of CD44, referred to as CD44H (haematopoietic) or CD44s (standard), is encoded by nine standard exons and has a molecular weight of approximately 90 kDa. CD44 variants contain additional exons, referred to as variant exons (v2-v10 in humans) that result in additional protein sequences being inserted into the extracellular, membrane proximal region of the protein.
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CD44 is believed to play an important role in lymphopoiesis with antibodies to CD44 blocking lymphopoiesis in long-term bone marrow cultures. However, the mild phenotype of the CD44 knockout mouse suggests that the role of CD44 is regulatory, rather than essential. Normal CD34 þ progenitors utilise CD44 to bind hyaluronic acid, which is a component of the bone marrow extracellular matrix and the best documented CD44 ligand. In addition to hyaluronic acid, CD44 interacts with a large number of extracellular matrix components including fibronectin, laminin, collagen, serglycin, osteopontin, chondroitin and heparan sulphate as well as cellular ligands including Eand L-selectin and CD44 itself. 1 Many of these ligand interactions are modulated by the inclusion of variant exons.
While the standard form of CD44 is expressed on virtually all haematopoietic cells, expression of larger splice variants is restricted, suggesting a more specialised function. Bone marrow progenitors can express exons v3, v6, v9 and v10, while lymphocytes and monocytes express exons v3, v6 and v9 following stimulation with inflammatory cytokines. 2 Expression of CD44 variants has been associated with poor prognosis and increased metastatic spread in a number of haematological and non-haematological malignancies. Increased levels of exons v6, v9 and v10 are associated with poor prognosis in non-Hodgkin's lymphoma and myeloma, and exon v6 with poor prognosis in acute myeloid leukaemia. 3 Most recently, exon v6 was shown to be expressed on bone marrow cells from patients with poor risk acute lymphoblastic leukaemia (ALL) but not on those from patients with a good prognosis. 4 In this study we examined the expression of CD44 variants in ALL and the effect of the expression of CD44 containing variant exon 6 on the engraftment and dissemination of ALL using a NOD/SCID mouse model of human leukaemia.
CD44 variant exon expression was examined in 12 cases of ALL by RT-PCR and Southern blotting. The region spanning the variant exon insertion point was amplified by RT-PCR. The 208 bp product representing CD44 standard was detected as a strong band in all cases. CD44 variant exons 3, 6 and 10 were detected in 11 of the 12 cases examined (Figure 1 ). Variant exons 3, 6 and 10 were clearly expressed in isolation (indicated by arrow heads), but in some instances larger products containing additional exons were detected (indicated by short and long arrows) ( Figure 1 ). Further PCR analysis using the forward primer from exon v3 and the reverse primer from exon v6 revealed the presence of exons v3 and v6 in combination. Considering the Southern blotting data it is highly likely that this is the major contributor to the 330 bp bands on the v3 and v6 Southern blots (short arrows). While it is likely that the 430 bp bands (long arrows) consist of exons v3 and v10 on the v3 blot and v6 and v10 on the v6 blot, we have not formally demonstrated the presence of these combinations. Variant exons 4, 5 and 7 were not detected in any cases, and only faint bands were observed for exons v8 and v9 in cases 2, 3, 4, 7 and 18. In each of these multiple species were present (data not shown). We have previously reported the presence of the variant exons 3 and 10 as single inserted exons in normal CD34 þ progenitors but variant exon 6 was undetectable using this methodology.
5 CD44 variant exon 6 has been detected by others on purified CD34
þ cells committed to the monocytic lineage. 3 However, the expression of CD44 variants on normal immature B cell precursors has not been studied.
To examine CD44v6 expression further, quantitative real-time PCR was performed on the original 12 patients and an additional nine patients. The expression of CD44v6 could be detected in all samples and ranged from 0.047 to 40.70% (median 3.00) of the value for GAPDH. Although there was no direct correlation between CD44v6 expression levels and disease-free survival using Cox Regression analysis (P ¼ 0.07), Kaplan-Meier analysis comparing patients with a relative CD44v6 expression of p1% with those 41% revealed a higher risk of disease relapse in the group expressing higher levels of CD44v6 (P ¼ 0.036) (HR 6.7, 95% CI 0.9-52.6) ( Figure 2 ). No correlation with overall survival could be detected although few events were scored. Although a larger case controlled study will be required to confirm the association between high CD44v6 expression and poor patient outcome, our data are consistent with the observation that CD44 variant exon 6 is preferentially expressed on cells from patients with medium to high-risk ALL. 4 To specifically examine the effect of CD44v6 expression on the behaviour of ALL, we transduced the CD44 negative pre-B ALL cell line, NALM6, with CD44H, CD44v6 or vector only. Both CD44 transduced cell lines demonstrated physiological levels of CD44 expression with comparable levels detected in the two cell lines (data not shown). NOD/SCID mice were injected by tail vein with 5 Â 10 6 transduced cells or the parental NALM6 cells. Using this model parental NALM6 cells induce leukaemia in the mice with hind limb paralysis and/or weight loss appearing by day 3479 (n ¼ 15). All mice receiving NALM6 cells expressing CD44v6 had lost greater than 10% of their body weight by day 19. In contrast only one-third of mice receiving NALM6 cells expressing CD44H had lost greater than 10% of their body weight. Due to the rapid onset of disease in mice receiving NALM6 cells expressing CD44v6 mice were killed on day 19 and in one of the four experiments on day 15. Bone marrow cells, peripheral blood and spleen cells were collected and analysed for the presence of leukaemic cells by flow cytometry. Mice receiving parental NALM6 cells or cells transduced with vector alone had similar levels of bone marrow engraftment with 36716% (n ¼ 8) of the marrow being of human origin in mice receiving parental and 3575% (n ¼ 4) in mice receiving vector transduced cells. Mice receiving cells transduced with CD44H had 2177% (n ¼ 9) leukaemic cells in the bone marrow. Although this was somewhat less than that observed for the parental and vector control, the difference was not statistically significant. In contrast, mice receiving cells expressing CD44v6 had significantly more leukaemic cells in the bone marrow (54715%, n ¼ 8) at the time of killing than mice receiving NALM6 expressing CD44H, vector control or parental cells (P ¼ 0.0004). Leukaemic cells were not detected in the peripheral blood of mice receiving parental or vector control NALM6 but were detected in two (20.7 and 2.6%) of four and two (24.0 and 5.1%) of five mice receiving CD44H or CD44v6 expressing cells respectively, although these differences were not statistically significant. Engraftment in the spleens of animals was extremely variable with no significant differences being detected. Leukaemic cells were observed within the epidural space of the spinal column in all animals examined, with invasion of the dorsal root ganglia being observed in some instances (Figure 3) . In all mice examined leukaemic cells were detected in the livers, although the livers were not visibly enlarged; however, infiltration of liver was more extensive in the mice receiving NALM6 cells expressing CD44v6 (Figure 3 ). Only occasional tumour deposits (defined as clusters of more than 10 cells) were observed in the livers of mice receiving parental NALM6 and NALM6 cells expressing CD44H (6.573.5 and 7.074.5 respectively per 10 low power Expression of CD44v6 is associated with a shorter disease-free survival in patients with ALL. CD44v6 was quantitated by real-time RT-PCR and cases were divided into low (r1% of GAPDH expression, dashed line) or high (41% of GAPDH, solid line) expression. DC44v6 expression was correlated with disease-free. NALM6 cells expressing CD44H or CD44v6 grew at identical rates in vitro. Proliferation rates were compared using 3 Hthymidine assays and total cell counts, with comparable results being obtained with both methods (data not shown). Similarly, there was no difference in proliferation rates when the cells were cultured in the presence of various stromal layers including Dexter stroma, bone marrow fibroblasts, bone marrow endothelial cells and the osteoblastic cell lines SOAS-2 and U2OS. Surprisingly, there was no alteration in the adhesion of these cells to hyaluronic acid or other CD44 ligands tested including fibronectin, laminin and collagens I and IV (data not shown). The failure of the transduced NALM6 cells to adhere to hyaluronic acid is consistent with the failure of pre-B ALL cells to bind this ligand despite expressing CD44. 6 None of the cell lines adhered significantly to collagens I or IV or to hyaluronic acid and all three cell lines bound similarly to fibronectin and laminin. All three cell lines adhered weakly to the osteoblastic cell lines, U2OS and SAOS-2 but strongly to Dexter stroma, fibroblasts and the bone marrow endothelial cell line HBMEC60 (data not shown).
Localisation of normal haematopoietic progenitors within the bone marrow is not random. It has been previously demonstrated that primitive haematopoietic progenitors localise close to the endosteum, with greater than 60% of cells being within 12 cells of the endosteum while less than 40% of more mature committed progenitors localise to this region. 7 In order to determine whether the increased engraftment rate of CD44v6 expressing NALM6 cells could be associated with altered bone marrow localisation, we injected mice with CFSE labelled parental NALM6 cells or NALM6 cells transduced with vector only, CD44H or CD44v6, and examined the localisation of these cells within the marrow 15 h later. The endosteal region has been previously defined as being within 12 cells of the endosteum and constitutes 13% of femoral bone marrow. Therefore, if the cells were randomly distributed within the marrow, 13% of the cells would be in the endosteal region. However, parental NALM6 cells as well as those expressing vector alone or CD44H showed a strong preference for the endosteal region, with 63.272.0 (n ¼ 5), 66.073.8 (n ¼ 4) and 66.475.5% (n ¼ 5) of cells being found in this location respectively (Figure 4 ). This is similar to the localisation of primitive Lin À Rh dull progenitors (66.075.6% (n ¼ 5)). In contrast, only 41.571.5% (n ¼ 4) of NALM6 cells expressing CD44v6 localised to this region (P ¼ 0.001), a pattern very similar to those observed for rapidly proliferating committed progenitors (o40% of cells endosteal) This distribution of normal progenitors suggests that the local microenvironment may influence cell proliferation and survival, with centrally localised cells proliferating more rapidly.
Expression of CD44 containing variant exon 6 has also been associated with disease progression and metastasis formation in a number of solid tumours. 1 More recently, CD44 variant exon 6 has been associated with a poor outcome in AML. 3 Legras et al also observed a shorter complete remission time in AML patients whose leukaemic cells expressed high levels of CD44 variant exon 6 and hypothesised that this may be due to an increased proliferation of residual blasts expressing variant exon 6. Our in vitro data with NALM6 cells expressing CD44H or CD44v6 did not reveal any difference in the rate of proliferation in vitro. However, it is possible that proliferation rates may differ in vivo. We observed a change in the localisation of cells within the marrow in response to CD44 variant exon 6 expression. The reasons for the altered localisation remain to be determined but are likely to include altered adhesive properties. Insertion of CD44 variant exons is known to modulate both the range of ligands recognised by CD44 and the affinity of binding. In addition, extracellular matrix components are not uniformly distributed throughout the marrow, with collagens I and IV associated with the endosteum and laminin and collagen IV with bone marrow vessels. The distribution of many other components has not been formally studied. It is therefore feasible that altered adhesion to matrix components could result in altered distribution within the bone marrow. CD44 is known to bind a large repertoire of ligands including the extracellular matrix components fibronectin, laminin, collagen, osteopontin, serglycin, chondroitin and heparan sulphates, hyaluronic acid, the cellular receptors L-and E-selectin and CD44 itself. 1 In this study we examined the adhesion of NALM6 cells to a number of matrix components and cellular layers without identifying differences in adhesion. However, many potential ligands remain to be tested. We therefore hypothesise that it is an as yet untested or possibly unidentified ligand for CD44, probably one specifically recognised by CD44 variant exon v6, which results in the altered bone marrow localisation of ALL cells within the bone marrow. A role for variant exon 6 in the hyaluronic acid-independent adhesion of plasma cells to bone marrow stroma supports this hypothesis. 8 In addition, ligation of CD44 can modulate cell proliferation and apoptosis. Whether altered CD44-mediated binding directly stimulates increased proliferation of survival of the ALL cells or whether it is other factors present in the microenvironmental niche that are responsible remains to be determined.
Expression of APO2.7, bcl-2 and bax apoptosis-associated proteins in CD34
À bone marrow cell compartments from patients with myelodysplastic syndromes Taking all these variables into consideration, in the present study, we have used four-colour stainings analysed by flow cytometry in order to evaluate specifically the expression of early apoptosis-related proteins in the mature BM compartments of mature nucleated red cells, myelomonocytic cells and lymphocytes in a series of 31 MDS patients, and compared them with corresponding cell compartments from the normal BM of 12 healthy donors. The markers analysed included the APO2.7/7A6 antigen -a 38 kDa mitochondrial membrane protein specifically expressed at the early stages of apoptosis, which has been reported as a valuable marker for the evaluation of apoptosis 2 -together with the antiapoptotic bcl-2 and the proapoptotic bax proteins. To the best of our knowledge, this is the first report in which these apoptosis-related proteins are specifically analysed in mature BM cell populations of both lowand high-risk MDS patients.
BM samples from a total of 31 MDS patients were collected at diagnosis (FAB classification: RA: 33%; RARS: 19%; RAEB: 33%; RAEB-t: 11%; and chronic myelomonocytic leukaemia: 4%) and processed within the first 24 h. MDS patients were also subclassified from the prognostic point of view according to both the International Prognosis Scoring System (IPSS) and the Spanish Prognosis Scoring System (SpPSS). Of the 31 MDS patients, 21 (68%) were classified as 'low-risk' MDS (IPSSp1.5 and SpPSSp3) and 10 (32%) as ' high-risk' MDS (IPSS41.5 and SpPSS43).
Erythrocyte-lysed, freshly obtained BM samples were analysed using a four-colour immunofluorescence technique for the simultaneous staining of surface and cytoplasmic (cyt) antigens according to well-established methods previously described in detail. 3 The following combinations of fluorochrome-conjugated (fluorescein isothiocyanate/phycoerythrin (PE)/PE-cyanine 5/allophycocyanine) monoclonal antibodies (MAb) were used: cyt bcl-2/CD32/CD34/CD45; cyt bax/CD32/CD34/CD45; and CD32/ cyt APO2.7/CD34/CD45. Appropriate isotype-matched negative controls were stained in parallel, as described previously.
3 BM cells were acquired in a FACScalibur flow cytometer (Becton Dickinson Biosciences-BDB, San José, CA, USA), using the CellQuest software program (BDB) and the PAINT-A-GATE PRO software program (BDB) for subsequent analysis. In each BM sample, the following subpopulations of CD34 À haematopoietic cells were identified on the basis of their unique CD45 expression and sideward light scatter (SSC) properties: (1) ). For each of these cell subsets, quantitative expression of cyt bcl-2, cyt bax and cyt APO2.7 was evaluated by the mean relative fluorescence intensity (RFI) obtained. 3 The results revealed significant differences in the reactivity for the three proteins among the different cell subsets analysed (Table 1) . Accordingly, bax expression was significantly lower (P ¼ 0.003) among nucleated red blood cells (mean RFI7s.d. of 0.970.2) as compared to the other cellular compartments (lymphocytes 1.470.5 and myelomonocytic cells 1.470.4). Similarly, intracellular levels of the APO2.7 protein were significantly lower (P ¼ 0.004) in myelomonocytic cells (6.773.2) as compared to both nucleated red cells (12.076.8) and lymphocytes (13.175.7). In addition, reactivity for the
